论文部分内容阅读
目的 观察地榆升白片对乳腺癌新辅助化疗后外周血象的影响。方法 6 9例乳腺癌患者分为观察组和对照组,两组术前接受CAF方案化疗2个疗程,化疗后均给予重组人粒细胞集落刺激因子(G CSF ,商品名:瑞白)治疗。末次化疗后2～3周患者血象恢复正常后接受乳腺癌改良根治术。观察组加服地榆升白片。观察两组外周血象变化及瑞白用量等指标。结果 观察组Ⅲ度及Ⅳ度骨髓抑制发生率12 . 5 % ,显著低于对照组的4 0 . 5 % (χ2 =3 95 ,P <0 . 0 5 ) ;观察组外周血WBC、PLT、Hb治疗后与治疗前差异无显著意义(P>0 . 0 5 ) ,对照组外周血WBC、PLT、Hb治疗后较治疗前明显下降,其中PLT差异有显著意义(P <0 . 0 5 ) ;观察组、对照组人均瑞白(10 0 μg)用量分别为(2 . 12±0 . 6 4 )支和(2 . 5 2±0 86 )支,差异有显著意义(t=2 16 ,P<0 . 0 5 )。结论 地榆升白片可预防乳腺癌化疗的骨髓抑制作用,提高PLT水平,降低WBC下降幅度,减少升白药的用量,值得推广。
Objective To observe the effects of Diyu Shengbai Tablets on peripheral blood after neoadjuvant chemotherapy for breast cancer. Methods Sixty-nine patients with breast cancer were divided into two groups: observation group and control group. Both groups received 2 cycles of CAF regimen preoperatively and were treated with recombinant human granulocyte-colony stimulating factor (G CSF). 2 to 3 weeks after the last chemotherapy patients with blood returned to normal after radical mastectomy. Observation group plus serving elm or white tablets. Observed two groups of peripheral blood changes and the amount of Swiss white index. Results The incidence of grade Ⅲ and Ⅳ myelosuppression in observation group was 12.5%, which was significantly lower than that in control group (χ2 = 955, P <0. 05). The WBC, PLT, There was no significant difference between Hb treatment and before treatment (P> 0.05). The WBC, PLT and Hb in the control group decreased significantly after treatment compared with those before treatment, in which PLT had significant difference (P <0.05) (2.12 ± 0.64) and (2.25 ± 86) branches respectively in the observation group and the control group, the difference was significant (t = 2 16, P <0. 05). Conclusion Di Yu Sheng Bai Tablet can prevent breast cancer chemotherapy bone marrow suppression, increase PLT levels, reduce the decline of WBC, reduce the amount of white matter, it is worth promoting.